S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?
NASDAQ:AMGN

Amgen (AMGN) Stock Price, News & Analysis

$270.90
+2.03 (+0.76%)
(As of 03/18/2024 ET)
Today's Range
$269.21
$273.58
50-Day Range
$268.87
$324.56
52-Week Range
$211.71
$329.72
Volume
3.61 million shs
Average Volume
3.10 million shs
Market Capitalization
$145.18 billion
P/E Ratio
21.69
Dividend Yield
3.32%
Price Target
$295.30

Amgen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
9.0% Upside
$295.30 Price Target
Short Interest
Healthy
2.06% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
1.11mentions of Amgen in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.91%
From $19.48 to $21.02 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.83 out of 5 stars

Medical Sector

46th out of 947 stocks

Biological Products, Except Diagnostic Industry

6th out of 159 stocks

AMGN stock logo

About Amgen Stock (NASDAQ:AMGN)

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Stock Price History

AMGN Stock News Headlines

Mastering Stocks in the Dow: Insights into the DJIA (AMGN)
What is the Dow Jones Industrial Average (DJIA)? The Dow Jones Industrial Average includes 30 companies, once all industrial companies. Learn more.
4 Oversold Large Cap Stocks Yielding High Dividends
As the market continues its relentless ascent to new heights, propelled by the surging tech sector and hype surrounding AI,  the murmurs of potential interest rate cuts by the Federal Reserve continue, and investors find themselves at a juncture where prudence meets opportunity.
They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
4 Oversold Large Cap Stocks Yielding High Dividends (AMGN)
Overlooked, oversold large-cap stocks offer compelling dividend yields for investors seeking income and potential capital appreciation
Amazon Stock: Why it's Finally Included in the Dow Index (AMGN)
Amazon replaced Walgreens in the Dow. While a positive move for Amazon, any impact on the stock's price may be limited due to low index weighting.
Amgen (NASDAQ:AMGN) Downgraded by StockNews.com to "Hold"
AMGN Mar 2024 282.500 call
Amgen Will Benefit From Increased Medical Spending
Like Tiny Crypto Retirement Funds
The crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds.
Amgen (NASDAQ:AMGN) Upgraded by StockNews.com to "Buy"
AMGN Apr 2024 270.000 call
AMGN Mar 2024 312.500 call
AMGN Mar 2024 282.500 put
AMGN Mar 2024 292.500 call
AMGN Mar 2024 370.000 call
AMGN Mar 2024 260.000 call
AMGN Jan 2026 350.000 put
AMGN Oct 2024 390.000 call
Amgen declares $2.25 dividend
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Ex-Dividend for 3/7 Dividend
2/15/2024
Dividend Payable
3/07/2024
Today
3/18/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
26,700
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$295.30
High Stock Price Target
$350.00
Low Stock Price Target
$200.00
Potential Upside/Downside
+9.0%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
18 Analysts

Profitability

Net Income
$6.72 billion
Pretax Margin
27.86%

Debt

Sales & Book Value

Annual Sales
$28.19 billion
Cash Flow
$26.30 per share
Book Value
$11.65 per share

Miscellaneous

Free Float
533,454,000
Market Cap
$145.18 billion
Optionable
Optionable
Beta
0.58

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Amgen was last updated on Sunday, March 17, 2024 at 4:30 PM.

Pros

Here are some ways that investors could benefit from investing in Amgen Inc.:

  • Amgen's diverse portfolio of products, including Enbrel, Prolia, and Repatha, cater to a wide range of medical conditions, providing revenue stability.
  • Strong research and development capabilities leading to innovative therapies like KYPROLIS for multiple myeloma, enhancing growth potential.
  • Collaboration agreements with key partners like AstraZeneca and Novartis for product development and commercialization, expanding market reach.
  • Recent positive clinical trial results for key products, such as Repatha, reducing cardiovascular risks, boosting investor confidence.
  • Current stock price showing consistent growth trends, indicating a favorable investment opportunity in the biotechnology sector.

Cons

Investors should be bearish about investing in Amgen Inc. for these reasons:

  • Increasing competition in the biotechnology industry may impact market share and pricing strategies for Amgen's products.
  • Regulatory challenges and uncertainties related to drug approvals and pricing could affect revenue streams and profitability.
  • Dependency on a few key products for a significant portion of revenue, exposing the company to risks of market fluctuations and patent expirations.
  • Potential impact of healthcare reforms or changes in reimbursement policies on product sales and profitability.
  • Market volatility and macroeconomic factors may influence investor sentiment towards biotech stocks like Amgen, leading to fluctuations in stock price.

AMGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings
or view top-rated stocks.

What is Amgen's stock price target for 2024?

18 analysts have issued twelve-month price objectives for Amgen's stock. Their AMGN share price targets range from $200.00 to $350.00. On average, they anticipate the company's stock price to reach $295.30 in the next year. This suggests a possible upside of 9.0% from the stock's current price.
View analysts price targets for AMGN
or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2024?

Amgen's stock was trading at $288.02 at the beginning of 2024. Since then, AMGN stock has decreased by 5.9% and is now trading at $270.90.
View the best growth stocks for 2024 here
.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our AMGN earnings forecast
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, February, 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.66 by $0.05. The medical research company had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a trailing twelve-month return on equity of 154.27%. Amgen's revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the company posted $4.09 EPS.
Read the conference call transcript
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, March 6th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share on Friday, June 7th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.32%. The ex-dividend date is Thursday, May 16th.
Read our dividend analysis for AMGN
.

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $9.00 per share and currently has a dividend yield of 3.31%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 72.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 42.82% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of 18.900-20.300 for the period, compared to the consensus EPS estimate of 20.000. The company issued revenue guidance of $32.4 billion-$33.8 billion, compared to the consensus revenue estimate of $32.7 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.15%), Vanguard Group Inc. (9.16%), Primecap Management Co. CA (2.73%), Charles Schwab Investment Management Inc. (1.94%), Capital Research Global Investors (1.25%) and Price T Rowe Associates Inc. MD (1.23%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends
.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
This page (NASDAQ:AMGN) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners